Literature DB >> 18029952

Rivastigmine-induced dystonia.

Clay J Pavlis1, Eric C Kutscher, Ryan M Carnahan, W Klugh Kennedy, Shawn Van Gerpen, Evelyn Schlenker.   

Abstract

PURPOSE: A case of acute dystonia related to rivastigmine use is reported.
SUMMARY: A 61-year-old Caucasian woman who had suffered from bipolar II disorder with rapid cycling for over 30 years was admitted to an inpatient psychiatry unit. In addition to bipolar II disorder, the patient had been previously diagnosed with early-stage Alzheimer's disease, posttraumatic stress disorder, and various anxiety disorders. During the current hospitalization, she was taking clonazepam, dextroamphetamine, lamotrigine, lansoprazole, levothyroxine, memantine, quetiapine, risperidone, rivastigmine, tranylcypromine, trazodone, and zolpidem. Soon after hospital admission, she began to complain of a tightening in her chest. A review of her records revealed similar complaints during previous hospitalizations. Rivastigmine was discontinued due to concerns of interactions with her antipsychotic regimen. Although these symptoms were previously attributed to anxiety, they appeared worse during this hospitalization. During these events she would be witnessed lying in bed in a supine position with her head canted posteriorly. Benztropine was given to help determine if she was having a dystonic reaction. Within 30 minutes, her chest discomfort began to resolve, and her symptoms resolved completely over the next 48 hours. Three days later, rivastigmine was restarted by the attending psychiatrist because of concerns about the patient's memory, and the dystonia-like symptoms returned within 2 hours of her morning dose. Rivastigmine was discontinued, and benztropine was given and then discontinued, with no return of symptoms for the remainder of her two-week hospitalization.
CONCLUSION: A patient with bipolar II disorder and mild-to-moderate Alzheimer's disease developed dystonia, possibly caused by rivastigmine. However, the patient was taking various other medications that could have lowered the threshold for extrapyramidal syndromes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18029952     DOI: 10.2146/ajhp060399

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  3 in total

1.  Peripheral cholinoceptor antagonist anisodamine counteracts cholinergic adverse effects and facilitates cognitive amelioration of rivastigmine.

Authors:  Wei-Wei Zhang; Zu-Peng Xu; Yong-Yao Cui; Hao Wang; Ming-Ke Song; Juan Li; Bi-Yun Shao; Zheng Xia; Hong-Zhuan Chen
Journal:  J Neural Transm (Vienna)       Date:  2009-09-12       Impact factor: 3.575

2.  A Case Report on Dyskinesia Following Rivastigmine Patch 13.3 mg/24 hours for Alzheimer's Disease: Perspective in the Movement Disorders Spectrum Following Use of Cholinesterase Inhibitors.

Authors:  Maria Cristina B Diaz; Raymond L Rosales
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.817

3.  Somatic comorbidities and Alzheimer's disease treatment.

Authors:  Alessandra Clodomiro; Pietro Gareri; Gianfranco Puccio; Francesca Frangipane; Roberto Lacava; Alberto Castagna; Valeria Graziella Laura Manfredi; Rosanna Colao; Amalia Cecilia Bruni
Journal:  Neurol Sci       Date:  2013-02-01       Impact factor: 3.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.